Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
Authors
Board, Ruth EWardley, Andrew M
Dixon, J Michael
Armstrong, Anne C
Howell, Sacha J
Renshaw, Lorna
Donald, Emma
Greystoke, Alastair
Ranson, Malcolm R
Hughes, Andrew
Dive, Caroline
Affiliation
Clinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, M20 4BX, UK.Issue Date
2010-04
Metadata
Show full item recordAbstract
Somatic mutations in PIK3CA (encoding a class I phosphoinositide 3 kinase (PI3K) subunit) modulate PI3K signalling to influence tumour behaviour and occur in up to 40% of breast cancers. Inhibitors of PI3K signalling are entering clinical trials, but the impact of PIKC3A mutation on tumour response has yet to be clarified. This study investigated the potential utility of circulating free DNA (cfDNA) as a source for PIK3CA mutation detection in patients with breast cancer. cfDNA extracted (QIAamp Virus spin kit) from blood and matched archival tumour from 46 patients with metastatic breast cancer and 30 patients with localised, operable breast cancer was assessed for hotspot PIK3CA mutations using Amplification Refractory Mutation System (ARMS()) allele-specific PCR and Scorpion probes. PIK3CA mutations were detected in 13/46 (28%) plasma-derived and 10/46 (21%) serum-derived cfDNA samples from metastatic breast cancer patients. In 41 cases with matched tumour and plasma-derived cfDNA data, concordance (same mutation status in plasma and tumour) was 95%. Where a PIK3CA mutation was present in tumour, the 'pick up' in plasma-derived cfDNA was 80%. PIK3CA mutations were present in tumours from 14/30 (47%) localised breast cancers, but no PIK3CA mutations were detected in matched cfDNA. These data demonstrate feasibility and potential utility of cfDNA for PIK3CA mutation detection in patients with metastatic breast cancer. Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways.Citation
Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer. 2010, 120 (2):461-7 Breast Cancer Res. Treat.Journal
Breast Cancer Research and TreatmentDOI
10.1007/s10549-010-0747-9PubMed ID
20107891Type
ArticleLanguage
enISSN
1573-7217ae974a485f413a2113503eed53cd6c53
10.1007/s10549-010-0747-9
Scopus Count
Collections
Related articles
- PIK3CA mutation associates with improved outcome in breast cancer.
- Authors: Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME
- Issue date: 2009 Aug 15
- A novel PIK3CA hotspot mutation in Isfahanian breast cancer patients.
- Authors: Gharbi S, Faghihi M, Tavassoli M
- Issue date: 2011 May
- PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
- Authors: Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME
- Issue date: 2011 Sep
- TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
- Authors: Hosny G, Farahat N, Hainaut P
- Issue date: 2009 Mar 18
- ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
- Authors: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Iwase H
- Issue date: 2018